Myeloid cells are the most abundant cells in the tumor microenvironment (TME). The tumor
recruits and modulates endogenous myeloid cells to tumor-associated macrophages (TAM) …

With the increasing promise of long-term survival with immune checkpoint blockade (ICB)
therapies, particularly for patients with advanced melanoma, clinicians and investigators are …

Abstract Background PD-L1 immunohistochemistry (IHC) has been traditionally used for
predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at …

Checkpoint molecules such as programmed cell death protein-1 (PD-1) and its ligand PD-L1
are critically required for tumor immune escape. The objective of this study was to …

Compared to solid tumors, the role of PD-L1 in hematological malignancies is less explored,
and the knowledge in this area is mostly limited to lymphomas. However, several studies …

Background: CTLA-4 impedes the immune system's antitumor response. There are two Food
and Drug Administration-approved anti-CTLA-4 agents–ipilimumab and tremelimumab–both …

Background: Programmed cell death-1 (PD-1) and PD ligand-1 (PD-L1) expression predict
the biological behaviour, aggressiveness, and response to immune checkpoint inhibitors in …

Simple Summary Immune checkpoint inhibitors (ICIs) have become a pillar of advanced
melanoma treatment. Given the moderate response rate to ICIs in metastatic melanoma …

Simple Summary Immune checkpoint inhibitors (ICIs) have been experimentally used in
refractory pituitary neuroendocrine tumours (PitNETs). We reviewed the published data on …

Lung cancer accounts for approximately 14% of all newly diagnosed cancers and is the
leading cause of cancer-related deaths. Chimeric RNA resulting from gene fusions (RNA …